A protective role for FGF-23 in local defence against disrupted arterial wall integrity?

Molecular and Cellular Endocrinology

Volumn 372, Issue 1-2, 2013, Pages 1-11

  Zhu, Dongxing ^a   Mackenzie, Neil C W ^a   Millan, Jose Luis ^b   Farquharson, Colin ^a   MacRae, Vicky E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Enpp1; FGF 23; Vascular calcification; Vascular smooth muscle cells

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CALCIUM; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KLOTHO PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT FIBROBLAST GROWTH FACTOR 23; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA STENOSIS; ARTERY CALCIFICATION; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TISSUE SECTION; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; CALCIUM; CELL SURVIVAL; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLUCURONIDASE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PRIMARY CELL CULTURE; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; VASCULAR CALCIFICATION;

EID: 84877100813     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.03.008     Document Type: Article

References (54)

1. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro-o M., Mohammadi M., Sirkis R., Naveh-Many T., Silver J. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 2007, 117:4003-4008.
2. Demer L.L., Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008, 117:2938-2948.
3. Ding H.T., Wang C.G., Zhang T.L., Wang K. Fibronectin enhances in vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells via ERK pathway. J. Cell. Biochem. 2006, 99:1343-1352.
4. Donate-Correa, J., Mora-Fernández, C., Martínez-Sanz, R., Muros-de-Fuentes, M., Pérez, H., Meneses-Pérez, B., Cazaña-Pérez, V., Navarro-González, J.F., in press. Expression of FGF23/KLOTHO system in human vascular tissue. Int. J. Cardiol. in press.
5. El-Abbadi M.M., Pai A.S., Leaf E.M., Yang H.Y., Bartley B.A., Quan K.K., Ingalls C.M., Liao H.W., Giachelli C.M. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 2009, 75:1297-1307.
6. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
7. Franceschi R.T., Ge C., Xiao G., Roca H., Jiang D. Transcriptional regulation of osteoblasts. Ann. NY. Acad. Sci. 2007, 1116:196-207.
8. Hu M.C., Shi M., Zhang J., Quiñones H., Griffith C., Kuro-o M., Moe O.W. Klotho deficiency causes vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 2011, 22:124-136.
9. Isakova T., Xie H., Yang W., Xie D., Anderson A.H., Scialla J., Wahl P., Gutiérrez O.M., Steigerwalt S., He J., Schwartz S., Lo J., Ojo A., Sondheimer J., Hsu C.Y., Lash J., Leonard M., Kusek J.W., Feldman H.I., Wolf M. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011, 305:2432-2439.
10. Johnson K., Polewski M., Terkeltaub R.A. Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ. Res. 2008, 102:529-537.
11. Khatiwala C.B., Peyton S.R., Metzke M., Putnam A.J. The regulation of osteogenesis by ECM rigidity in MC3T3-E1 cells requires MAPK activation. J. Cell Physiol. 2007, 211:661-672.
12. Kok K., Geering B., Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem. Sci. 2009, 34:115-127.
13. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K.P., Baum M.G., Schiavi S., Hu M.C., Moe O.W., Kuro-o M. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 2006, 281:6120-6123.
14. Lim K., Lu T.S., Molostvov G., Lee C., Lam F.T., Zehnder D., Hsiao L.L. Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012, 125:2243-2255.
15. Liu S., Tang W., Fang J., Ren J., Li H., Xiao Z., Quarles L.D. Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol. Endocrinol. 2009, 23:1505-1518.
16. Liu F., Wu S., Ren H., Gu J. Klotho suppresses RIG-I-mediated senescence-associated inflammation. Nat. Cell. Biol. 2011, 13:254-262.
17. Lorenz-Depiereux B., Schnabel D., Tiosano D., Häusler G., Strom T.M. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am. J. Hum. Genet. 2010, 86:267-272.
18. Mackenzie N.C., MacRae V.E. The role of cellular senescence during vascular calcification: a key paradigm in aging research. Curr. Aging Sci. 2011, 4:128-136.
19. Mackenzie N.C., Zhu D., Longley L., Patterson C.S., Kommareddy S., MacRae V.E. MOVAS-1 cell line: a new in vitro model of vascular calcification. Int. J. Mol. Med. 2011, 27:663-668.
20. -/- Mice. PLoS One 2012, 7:e32177.
21. Mackenzie N.C.W., Huesa C., Rutsch F., MacRae V.E. New insights into NPP1 function: lessons from clinical and animal studies. Bone 2012, 51:961-968.
22. MacRae V.E., Farquharson C., Ahmed S.F. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J. Endocrinol. 2006, 189:319-328.
23. MacRae V.E., Burdon T., Ahmed S.F., Farquharson C. Ceramide inhibition of chondrocyte proliferation and bone growth is IGF-I independent. J. Endocrinol. 2006, 191:369-377.
24. MacRae V.E., Ahmed S.F., Mushtaq T., Farquharson C. IGF-I signalling in bone growth: inhibitory actions of dexamethasone and IL-1beta. Growth Horm. IGF Res. 2007, 17:435-439.
25. MacRae V.E., Horvat S., Pells S.C., Dale H., Collinson R.S., Pitsillides A.A., Ahmed S.F., Farquharson C. Increased bone mass, altered trabecular architecture and modified growth plate organization in the growing skeleton of SOCS2 deficient mice. J. Cell. Physiol. 2009, 218:276-284.
26. MacRae V.E., Davey M.G., McTeir L., Narisawa S., Yadav M.C., Millán J.L., Farquharson C. Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chick. Bone 2010, 46:1146-1155.
27. Medici D., Razzaque M.S., Deluca S., Rector T.L., Hou B., Kang K., Goetz R., Mohammadi M., Kuro O.M., Olsen B.R., Lanske B. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J. Cell. Biol. 2008, 182:459-465.
28. Murshed M., Harmey D., Millán J.L., McKee M.D., Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes. Dev. 2005, 19:1093-1104.
29. Nasrallah M.M., El-Shehaby A.R., Salem M.M., Osman N.A., El Sheikh E., El Din U.A.Sharaf Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol. Dial. Transplant. 2010, 25:2679-2685.
30. Rakugi H., Matsukawa N., Ishikawa K., Yang J., Imai M., Ikushima M., Maekawa Y., Kida I., Miyazaki J., Ogihara T. Anti-oxidative effect of Klotho on endothelial cells through cAMP activation. Endocrine 2007, 31:82-87.
31. Razzaque M.S., Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J. Endocrinol. 2007, 194:1-10.
32. Roy J., Kazi M., Hedin U., Thyberg J. Phenotypic modulation of arterial smooth muscle cells is associated with prolonged activation of ERK1/2. Differentiation 2001, 67:50-58.
33. Rutsch F., Vaingankar S., Johnson K., Goldfine I., Maddux B., Schauerte P., Kalhoff H., Sano K., Boisvert W.A., Superti-Furga A., Terkeltaub R. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am. J. Pathol. 2001, 158:543-554.
34. Rutsch F., Ruf N., Vaingankar S., Toliat M.R., Suk A., Höhne W., Schauer G., Lehmann M., Roscioli T., Schnabel D., Epplen J.T., Knisely A., Superti-Furga A., McGill J., Filippone M., Sinaiko A.R., Vallance H., Hinrichs B., Smith W., Ferre M., Terkeltaub R., Nürnberg P. Mutations in Enpp 1 are associated with 'idiopathic' infantile arterial calcification. Nat. Genet. 2003, 34:379-381.
35. Saito Y., Nakamura T., Ohyama Y., Suzuki T., Iida A., Shiraki-Iida T., Kuro-o M., Nabeshima Y., Kurabayashi M., Nagai R. In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem. Biophys. Res. Commun. 2000, 276:767-772.
36. Salasznyk R.M., Klees R.F., Hughlock M.K., Plopper G.E. ERK signaling pathways regulate the osteogenic differentiation of human mesenchymal stem cells on collagen I and vitronectin. Cell. Commun. Adhes. 2004, 11:137-153.
37. Sali A., Favaloro J.M., Terkeltaub R., Goding J.W. Germline deletion of the nucleoside triphosphate pyrophosphohydrolase (NTPPPH) plasma cell membrane glycoprotein-1 (PC-1) produces abnormal calcification of periarticular tissues. Ecto-ATPases and Related Ectoenzymes 1999, 267-282. Shaker Publishing, The Netherlands. L. Vanduffel, R. Lemmems (Eds.).
38. Shalhoub V., Shatzen E.M., Ward S.C., Davis J., Stevens J., Bi V., Renshaw L., Hawkins N., Wang W., Chen C., Tsai M.M., Cattley R.C., Wronski T.J., Xia X., Li X., Henley C., Eschenberg M., Richards W.G. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Invest. 2012, 122:2543-2553.
39. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., Takeuchi Y., Fujita T., Fukumoto S., Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. USA 2001, 98:6500-6505.
40. Shimada T., Urakawa I., Yamazaki Y., Hasegawa H., Hino R., Yoneya T., Takeuchi Y., Fujita T., Fukumoto S., Yamashita T. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 2004, 314:409-414.
41. Shroff R.C., Shanahan C.M. The vascular biology of calcification. Semin. Dial. 2007, 20:103-109.
42. Simmons C.A., Nikolovski J., Thornton A.J., Matlis S., Mooney D.J. Mechanical stimulation and mitogen-activated protein kinase signaling independently regulate osteogenic differentiation and mineralization by calcifying vascular cells. J. Biomech. 2004, 37:1531-1541.
43. Sitara D., Razzaque M.S., Hesse M., Yoganathan S., Taguchi T., Erben R.G., Jüppner H., Lanske B. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004, 23:421-432.
44. Sitara D., Kim S., Razzaque M.S., Bergwitz C., Taguchi T., Schüler C., Erben R.G., Lanske B. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet. 2008, 4:e1000154.
45. Speer M.Y., Chien Y.C., Quan M., Yang H.Y., Vali H., McKee M.D., Giachelli C.M. Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro. Cardiovasc. Res. 2005, 66:324-333.
46. Speer M.Y., Yang H.Y., Brabb T., Leaf E., Look A., Lin W.L., Frutkin A., Dichek D., Giachelli C.M. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ. Res. 2009, 104:733-741.
47. Srivaths P.R., Goldstein S.L., Silverstein D.M., Krishnamurthy R., Brewer E.D. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr. Nephrol. 2011, 26:945-951.
48. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., Fujita T., Fukumoto S., Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
49. Voigt M., Fischer D.C., Rimpau M., Schareck W., Haffner D. Fibroblast growth factor (FGF)-23 and fetuin-A in calcified carotid atheroma. Histopathology 2010, 56:775-788.
50. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J. Am. Soc. Nephrol. 2010, 21:1427-1435.
51. Yamamoto M., Clark J.D., Pastor J.V., Gurnani P., Nandi A., Kurosu H., Miyoshi M., Ogawa Y., Castrillon D.H., Rosenblatt K.P., Kuro-o M. Regulation of oxidative stress by the anti-aging hormone klotho. J. Biol. Chem. 2005, 280:38029-38034.
52. Yilmaz M.I., Sonmez A., Saglam M., Yaman H., Kilic S., Demirkaya E., Eyileten T., Caglar K., Oguz Y., Vural A., Yenicesu M., Zoccali C. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int. 2010, 78:679-685.
53. Zhu D., Mackenzie N.C.W., Millán J.L., Farquharson C., MacRae V.E. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011, 6:e19595.
54. Zhu D., Mackenzie N.C.W., Farquharson C., MacRae V.E. Mechanisms and clinical consequences of vascular calcification. Front. Endocrinol. 2012, 3:95.